Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)




    www.akelapharma.com
    Toronto Stock Exchange Symbol: AKL

    MONTREAL, Feb. 4 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has received notice from the FDA that,
due to GLP deviations the 6-month inhalation toxicology studies were deemed
invalid. No toxicological reasons were cited. We are currently evaluating
several alternative remedies and are confident that the submission for
regulatory approval will not be delayed by more than 6 months.

    Conference call information:

    Akela will host a conference call at 9:00 am, on Monday February 4, 2008.
Interested parties may also access the conference call by webcast at
www.akelapharma.com.
    The telephone numbers to access the conference call are 1-800-732-9303 or
416-644-3415. A replay of the call will be available until February 11, 2008.
The telephone numbers to access the replay are 416-640-1917 and 1-877-289-8525
with code number 21262067#.

    About Akela Pharma Inc.:

    Akela Pharma is an integrated drug development company focused on
developing therapies for the growing multi-billion dollar inhalation and pain
markets. Its lead product, for the treatment of breakthrough cancer pain, is a
fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry
powder inhaler platform. Its pipeline also includes therapeutics for asthma,
COPD, growth hormone deficiencies and controlled substance abuse deterrent
formulations.
    Akela's common shares trade on The Toronto Stock Exchange ("TSX") under
the symbol "AKL" with 11.7 million shares outstanding.

    This news release contains certain forward-looking statements that
reflect the current views and/or expectations of Akela Pharma Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
    %SEDAR: 00003466EF




For further information:

For further information: visit Akela's website at www.akelapharma.com,
or contact: Frédéric Dumais, Vice-President, Investor Relations, (514)
315-3330 ext. 106, Fax: (514) 315-3325

Organization Profile

Akela Pharma Inc

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890